---
layout: default
title: Serine
parent: 僅模型預測 (L5)
nav_order: 612
evidence_level: L5
indication_count: 10
---

# Serine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Serine: From Unspecified Indication to Familial Visceral Myopathy

## One-Sentence Summary

Serine is an amino acid drug substance with 55 active registrations in Malaysia, but its originally approved indication and mechanism of action are not recorded in the current data extract. The TxGNN model predicts potential efficacy for **Familial Visceral Myopathy**, with a prediction score of 99.99% — however, this direction is currently supported by **zero clinical trials** and **zero publications**, making it a model-only prediction with no independent verification.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not specified in available regulatory data |
| Predicted New Indication | Familial Visceral Myopathy |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 55 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Serine, and its originally approved indication text is also missing from the 55 Malaysia license records retrieved. Without either data point, no mechanistic bridge can be established between Serine's known pharmacology and Familial Visceral Myopathy.

The prediction itself is generated purely by the TxGNN knowledge-graph model (score 0.9999, rank 306 among candidates) — no supporting clinical trial or literature evidence was found when the evidence collectors queried for "Serine" + "familial visceral myopathy." The model's own rationale notes explicitly that no mechanistic hypothesis can currently be constructed.

It is worth noting that for several lower-ranked candidates in this same evidence pack (e.g., intestinal obstruction, angle-closure glaucoma), literature was retrieved — but on inspection it relates to the *serine protease* enzyme family (e.g., PRSS56, MK2 signaling) rather than the amino acid Serine itself. This is a naming collision, not pharmacological evidence, and should not be mistaken for support of the drug-repurposing hypothesis.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Malaysia Market Information

Serine has 55 active registrations with the Malaysia NPRA (marketed status: ✓ Marketed). However, product-level details — license numbers, product names, dosage forms, manufacturers, and approved indication text — were not populated in the current data extract and cannot be reported here.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked predicted indication (Familial Visceral Myopathy) is supported by no clinical trials and no literature — it is an unverified, model-only prediction (Evidence Level L5). Combined with missing mechanism-of-action data and missing package-insert safety information (a blocking data gap for safety pre-assessment), there is currently no basis to advance this candidate.

**To proceed, the following is needed:**
- TFDA/NPRA package insert warnings and contraindications (blocking gap — required before any S1 safety pre-assessment)
- Mechanism of action data via DrugBank query
- Original approved indication text for the 55 Malaysia-registered products
- Independent clinical or preclinical evidence specific to Familial Visceral Myopathy, since none currently exists
- Disambiguation review of secondary candidates (e.g., intestinal obstruction, angle-closure glaucoma) to confirm retrieved literature reflects the amino acid Serine and not unrelated serine protease enzymes
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

